0

Atopic Dermatitis - A Pipeline Analysis Report

  • Published: Jun 2018
  • Pages: 300
  • SKU: IRTNTR22527
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the drug development landscape of the drug development for Atopic dermatitis including molecules at pre-clinical, discovery, and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapies employed, route of administration, therapeutic modalities, targets for drug development, and mechanism of action.

Overview of the drug development pipeline for atopic dermatitis

Atopic dermatitis (AD) is a chronic disease and is also known as eczema. It is a non-contagious inflammatory skin condition that is characterized by itchy dry skin, and on scratching, clear fluid may come out. AD is usually associated with elevated immunoglobulin E (IgE) levels. Researchers have come up with numerous drugs in various phases of drug development, targeting AD pathogenesis. Technavio’s market research analysts have predicted that with the introduction of molecules under development and molecules in discovery as some of the most promising approaches to treat multiple sclerosis, the global atopic dermatitis market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical and phase II developmental stages. For instance, sponsors such as AbbVie developed ABT-494 and Alchem Laboratories developed NanoDox, which are under phase II development stage. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under discovery, phase I, and phase III stages. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase I/II developmental stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of atopic dermatitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

  • Bioleaders
  • Cutanea
  • Dermira

Therapeutic assessment of the drug development pipeline for atopic dermatitis by route of administration

  • Topical
  • Oral
  • Subcutaneous
  • Intravenous
  • Oral/Topical

The topical route of administration (ROA) involves the administration of drug substances on the skin. It has been observed that the majority of total therapeutics are being developed for topical administration.

Therapeutic assessment of the drug development pipeline for atopic dermatitis by therapeutic modalities

  • Small molecule
  • Monoclonal antibody
  • Biological
  • Plant derived
  • Steroid
  • Peptide

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for atopic dermatitis are being developed as small molecules. Small molecules include lipids, monosaccharides, second messengers, as well as drugs and other xenobiotics organic compounds.

Key questions answered in the report include

  • What are the drug development molecules in the various development stages for atopic dermatitis?
  • What are the companies that are currently involved in the development of drug molecules for atopic dermatitis?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.

 

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

 

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>